Pharmacokinetic and safety study of subcutaneously administered weekly ING-1, a human engineered™ monoclonal antibody targeting human EpCAM, in patients with advanced solid tumors

Annals of Oncology

Volumn 18, Issue 10, 2007, Pages 1704-1707

  Goel, S ^a,c   Bauer, R J ^b   Desai, K ^a   Bulgaru, A ^a   Iqbal, T ^a   Strachan, B K ^a   Kim, G ^a   Kaubisch, A ^a   Vanhove, G F ^b   Goldberg, G ^a   Mani, S ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b XOMA Corporation   (United States)

^c Jack D Weiler Hospital   (United States)

Author keywords

Cancer; EpCAM; ING 1; Pharmacokinetics; Phase I

Indexed keywords

ANALGESIC AGENT; EPITHELIAL CELL ADHESION MOLECULE; EPITHELIAL CELL ADHESION MOLECULE ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY ING 1; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ANTIBODY RESPONSE; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CANCER; DIARRHEA; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; FEMALE; HALF LIFE TIME; HUMAN; LUNG DISEASE; LYMPHOCYTOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PANCREATITIS; PARTIAL THROMBOPLASTIN TIME; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; REPEATED DRUG DOSE; RISK ASSESSMENT; SIDE EFFECT; SOLID TUMOR; VOMITING;

AGED; AGED, 80 AND OVER; ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CELL ADHESION MOLECULES; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; NEOPLASMS;

EID: 34848842124     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm280     Document Type: Article

References (17)

1. ™ monoclonal antibody to epithelial cell adhesion molecule. Neoplasia 2003; 5: 146-154.
2. Velders MP, Litvinov SV, Wamaar SO et al. New chimeric anti-pancarcinoma monoclonal antibody with superior cytotoxicity-mediating potency. Cancer Res 1994; 54: 1753-1759.
3. Velders MP, van Rhijn CM, Briaire IH et al. Immunotherapy with low and high affinity monoclonal antibodies 17-1A and 323/A3 in a nude muse xenograft carcinoma model. Cancer Res 1995; 55: 4398-4403.
4. Velders MP, van Rhijn CM, Cornelissen IM et al. The role of monoclonal antibody affinity in tumor immunotherapy evaluated in in vivo models for minimal residual disease. J Immunother Emphasis Tumor Immunol 1996; 19: 245-256.
5. Kievit E, Pinedo HM, Schluper HM et al. Comparison of monoclonal antibodies 17-1A and 323/A3: The influence of the affinity on tumour uptake and efficacy of radioimmunotherapy in human ovarian cancer xenografts. Br J Cancer 1996; 73: 457-464.
6. Kumar S, Vinci JM, Pytel BA et al. Expression of messenger RNAs for complement inhibitors in human tissues and tumors. Cancer Res 1993; 53: 348-353.
7. Gorter A, Blok VT, Haasnoot WH et al. Expression of CD46, CD55, and CD59 on renal tumor cell lines and their role in preventing complement-mediated tumor cell lysis. Lab Invest 1996; 74: 1039-1049.
8. Herlyn D, Koprowski H. IgG2a monoclonal antibodies inhibit human tumor growth, through interaction with effector cells. Proc Natl Acad Sci USA 1982; 79: 4761-4765.
9. Huls GA, Heijnen IA, Cuomo ME et al. A recombinant, fully human monoclonal antibody with antitumor activity constructed from phage-displayed antibody fragments. Nat Biotechnol 1999; 17: 276-281.
10. de Bono JS, Tolcher AW, Forero A et al. ING-1, a monoclonal antibody targeting Ep-CAM in patients with advanced adenocarcinomas. Clin Cancer Res 2004; 10: 7555-7565.
11. Miller AB, Hoogstraten B, Staquet M et al. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
12. Gibaldi N, Perrier D. Pharmacokinetics, 2nd edn. New York: Marcel Dekker 1982, chapter 2.
13. Saleh M, Posey J, Khazaeli M et al. Phase I trial testing multiple doses of humanized monoclonal antibody (MAb) 3622W94. Proc Am Soc Clin Oncol 1998; 17: 436.
14. LoBuglio A, Saleh M, Braddock J et al. A phase I trial of the humanized anti-EGP40 monoclonal antibody 3622W94 [abstract]. Proc Am Soc Clin Oncol 1997; 16: 436.
15. Takiyama Y, Tempero MA, Takasaki H et al. Reactivity of CO17-1A and B72.3 in benign and malignant pancreatic diseases. Hum Pathol 1989; 20: 832-838.
16. Balzar M, Winter MJ, de Boer CJ et al. The biology of the 17-1A antigen (Ep-CAM). J Mol Med 1999; 77: 699-712.
17. Mire-Sluis AR, Barrett YC, Devanarayan V et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunological Methods 2004; 289: 1-16.